Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib DDI study with CYP3A4/5 and CYP2C9 probes
NCT03245307Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Aug 2017
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Rivoceranib in solid tumor, sponsored by Hengrui. Primary endpoint: Area under the plasma concentration versus time curve. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03245307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03245307.